Why AbbVie Is Still a Stock to Buy After Last Week's Plunge

AbbVie Inc., a biotech stock we like, took a hit last week following disappointing mid-phase trial results for one of its pipeline drugs. We see no reason to change our recommendation: This stock is still poised for long-term growth. Find out why Wall Street's overreaction could be your gain... Tags: biotech stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why AbbVie Is Still a Stock to Buy After Last Week's Plunge appeared first on Money Morning - We Make Investing Profitable .